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A b s t r a c t
Introduction: Systemic lupus erythematosus (SLE) is prevalent among young
female adults, particularly in Asia. In Taiwan, features of end-of-life SLE patients
remain unclear.
Material and methods: Data regarding SLE patients whose hospitalization end-
ed up with death were collected and analyzed from the repository of the Nation-
al Health Insurance Research Database, Taiwan, from 2005 to 2007.
Results: A total of 302 subjects were enrolled and the majority of these were
young to middle-aged women (45.8 ±18.5 years); only one third of them were
treated by rheumatologists. Eight patients (2.6%) with comorbid cancers received
hospice care. Sepsis/bacteremia (42.1%) was the major acute comorbidity.
Nephropathy/nephritis (35.1%) represented the major chronic comorbidity.
Among 27 subjects with comorbid cancers, gynecological cancers were the most
common (18%). Among the inpatient costs, the cost of prescriptions account-
ed for the majority (21.7 ±11.5%). Under a multivariate logistic regression,
advanced age (≥ 65 years) correlated positively with acute lower respiratory
conditions (ALRC) and diabetes mellitus (DM), and male gender correlated neg-
atively with nephropathy/nephritis. The nephropathy/nephritis correlated pos-
itively with hospital stays > 14 days. The ALRC was closely associated with acute
respiratory failure, but not with shock. However, shock was closely associated
with hospital stays ≤ 14 days and sepsis/bacteremia. Cancer development was
inversely correlated to nephropathy/nephritis, acute respiratory failure, and
shock (all p < 0.05). 
Conclusions: The end-of-life SLE patients revealed aforementioned characteris-
tics and relationships. Sepsis/bacteremia, acute respiratory failure, and ALRC
contributed most frequently to the ultimate death of acutely ill SLE patients.
Key words: comorbidity, retrospective study, impending death, systemic lupus 
erythematosus.
Introduction
Systemic lupus erythematosus (SLE) is prevalent among young
women, particularly in non-Caucasian populations. Patients are frequently
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originating from Gram-negative bacteria [1]. In the
USA, the increase in the number and the cost of
avoidable hospitalizations has been remarkable
among SLE patients [2]. Regarding mortality,
a Mexican report has revealed a correlation
between active lupus nephritis (LN) and infections
[3]. A nationwide claim-based study in the USA
has found that African Americans have higher
mortality due to SLE than Caucasians [4]. Ward et
al. reported the predictors of mortality such as
age, sepsis, LN, respiratory failure and other
indices among inpatients with SLE [5]. It is report-
ed that lower socio-economic status correlated
with in-hospital mortality rate of patients with SLE
[6]. For genetic issues, the relationship between
some genetic mutations and development of SLE
has been discussed [7].
In Taiwan, National Health Insurance (NHI),
which was launched in 1995, categorizes SLE as
a catastrophic illness. According to the standard
diagnostic criteria set forth by the American Col-
lege of Rheumatology (ACR) [8, 9], those who are
identified by clinical rheumatologists as having
SLE as a catastrophic illness are exempt from the
cost incurred by this disease in ambulatory as well
as in-hospital cares [10]. Therefore, a complete
registry of SLE has been established since then.
A Taiwanese epidemiological study has revealed
a trend of increasing prevalence but a declining
incidence of SLE, and its incidence and prevalence
in Taiwan were both higher than those in West-
ern countries [11]. Another claim-based study has
reported a significant role of experienced physi-
cians in care of SLE patients, which can reduce in-
hospital mortality from the disease [12]. Howev-
er, the end-of-life issues of SLE patients in Taiwan
remain unclear. 
The aim of this investigation was to delineate
aforementioned issues from the repository of the
database in NHI. 
Material and methods
Design of the study
Retrospective and claim-based analyses were con-
ducted by collecting data regarding end-of-life hos-
pitalization of patients with SLE from the National
Health Insurance Research Database (NHIRD) from
2005 to 2007. The NHIRD is maintained by the
National Health Research Institute, Taiwan, and pro-
vides anonymous/encrypted NHI claim data to local
academic institutes for related studies [13]. Hospi-
talization claim data (DD 2005.DAT, DD 2006.DAT, and
DD2007.DAT) were screened with the International
Classification of Diseases, the 9th Revision Clinical
Modification (ICD-9-CM) code of 710.0. The reason
for discharge included in-hospital death, suicide, and
critical discharge for home death (which is a ritual
belief of getting peace in another world abided by
many Taiwanese). For accuracy of coding, those who
were not registered with catastrophic illness in the
NHI were excluded from the study. The study design
is shown in Figure 1. 
Parameters
Subjects’ general data, comorbidities and claims
for charges were analyzed. The details of inpatients’
costs were converted into United States Dollars
(USD) according to the closing exchange rate on
December 31, 2007. The comorbidities were collect-
ed according to related ICD-9-CM codes, which
included sepsis or bacteremia (code 038.x, 790.7),
acute respiratory failure (code 518.81), non-traumat-
ic shock (code 785.5x), acute myocardial infarction
(410.x, 411.x), acute cerebrovascular accident (code
430.x-434.x), acute low respiratory conditions (ALRC)
(code 466.x, 480.x-486.x), urological infections (code
590.x, 595.x, 597.x, 599.x, 601.x), peptic ulcer or
esophagitis (code 530.x-534.x), hypertensive diseases
(code 401.x-405.x), heart failure (code 428.x), dia-
betes mellitus (DM, code 250.x), cancers (code 140.x-
208.x) and nephropathy/nephritis (code 580.x-589.x,
791.0). Psychiatric disorders were not included due
to possible underestimation of ICD coding in end-of-
life hospitalizations. The study was conducted after
approval by the National Health Research Institute,
Taiwan (No. 99237). All the identity data of subjects
was encrypted and analyzed anonymously.
Statistical analysis
Data in the text and tables are expressed as
mean ± SD. SPSS software (version 17.0, SPSS Inc.,
Chicago, IL, USA) was used for multivariate logistic
regression analysis to assess statistical significance.
The correlated factors were presented as regres-
sion coefficient (B), odds ratio (OR) and 95% confi-
dence interval (CI). A p value of less than 0.05 was
considered statistically significant (2-tailed tests).
Figure 1. Algorithm for case collection
22,484 Discharges with diagnosis of SLE
in 2005-2007 (ICD-9-CM code 710.0)
362 Discharges resultated in in-hospital
death or critical discharge for home death
60 Discharges without registration for
catastrophic illness (excluded)
302 Discharges with registration for
catastrophic illness (included)
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Results
From 2005 to 2007, a total of 22,484 hospital dis-
charges regarding patients with SLE were record-
ed; three hundred and two mortality discharges ful-
filling the criteria for this study were included. The
total number of patients holding a catastrophic cer-
tificate with a code of 710.0 during 2005 to 2006
was retrieved. No case was registered as suicide as
the result of end-of-life hospitalization. As shown
in Table I, estimated incidence and prevalence of
SLE during these two years were 3.34/105, 3.03/105
and 69.33/105, 72.08/105 respectively.
Table II shows the demographic characteristics
of these dead patients with SLE (N = 302). The
majority of patients were young to middle-aged
(45.8 ±18.5 years) women (86.4%), who were admit-
ted to non-hospice (acute) wards (97.4%) affiliat-
ed to Internal Medicine (81.8%; including rheuma-
tology, which accounted for 31.5% of all subjects).
The average inpatient cost for each admission, its
detailed items and ratios to the total costs, are listed
in Table III. Drug prescriptions represented the major-
ity of the total cost of hospitalization (21.7 ±11.5%),
followed by laboratory examinations (12.4 ±7.6%). 
Table IV lists the major comorbidities. Sep-
sis/bacteremia (42.1%) and acute respiratory failure
(38.7%) were the most common acute comorbidi-
ties and nephropathy/nephritis (35.1%) accounted
for the majority of chronic comorbidities. Among 
27 patients with co-existing cancers, eight received
hospice care. Gynecological cancers (5 subjects,
18.5% of those with cancers; 1.7% of the total), lung
cancers (4 subjects, 14.8% of those with cancers;
1.3% of the total), colorectal cancers, leukemia/lym-
phoma and metastatic cancer with unknown origin
(3 subjects in each category, 11.1% of those with can-
cers; 1.0% of the total) accounted for approximate-
ly half of those with co-existing cancers.
As demonstrated in Table V, elderly patients tend-
ed to be men (B = 1.022, OR = 2.778) and to have DM
(B = 1.935, OR = 6.926) and ALRC (B = 0.880, OR =
2.411) more frequently but to have nephropathy/
nephritis less frequently (B = –0.974, OR = 0.377) as
analyzed by multivariate logistic regression. Nephropa-
Table I. The prevalence and incidence of SLE in 2005 and 2006 in Taiwan
Date Population Identified cases Prevalence New cases Incidence
(year-month-day) (cases/105) (cases/105)
2005-1-1 NA 14,995 NA NA NA
2005-12-31 22,722,559 15,753 69.33 758 3.34
2006-1-1 NA 15,753 NA NA NA
2006-12-31 22,814,639 16,444 72.08 691 3.03
NA – not applicable
Table II. Demographic characteristics of patients with
SLE who died in or just after the last admission dur-
ing 2005-2007 (N = 302)
Items Counts [%]
Mean age [years]* 45.8 ±18.5
Mean hospital stay [days] 20.4 ±18.1
Gender (male/female) 41/261
Hospice care (yes/no) 8/294
Departments to which admissions were assigned
Family medicine 4 (1.3)
Internal medicine (general internal) 33 (10.9)
Internal medicine (rheumatology) 95 (31.5)




Other sections  4 (1.3)
*The subjects’ median age is 44 years old
Table III. Costs of the end-of-life hospitalization incurred for patients with SLE during 2005-2007 (N = 302)
Items Costs [USD] Ratio to total costs [%]
Laboratory tests 964.7 ±935.1 12.4 ±7.6
Radiological examinations 276.9 ±375.4 3.7 ±5.8
Blood products for transfusion 429.9 ±819.5 3.7 ±6.3
Hemodialysis (excluding peritoneal dialysis) 1,204.5 ±2115.7 9.7 ±9.6
Drug prescriptions 2,224.4 ±2929.0 21.7 ±11.5
Total 9,530.2 ±10354.2 100
*USD, United States dollars
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thy/nephritis correlated positively with hospital stays
of more than 14 days (B = 0.566, OR = 1.761). The
ALRC was closely associated with acute respiratory
failure (B = 0.733, OR = 2.081), but not with non-trau-
matic shock (B = –0.855, OR = 0.425). Indeed, non-
traumatic shock tended to be associated with short-
er hospital stays (≤ 14 days, B = 0.901, OR = 2.463)
and sepsis/bacteremia (B = 1.852, OR = 6.369). On
the other hand, cancers occurred less frequently in
subjects with nephropathy/nephritis (B = –2.006, 
OR = 0.135), acute respiratory failure (B = –1.092, 
OR = 0.336), or non-traumatic shock (B = –2.716, 
OR = 0.113).
Discussion
For demographic characteristics and the role
of rheumatologists
As demonstrated in Table II, the majority of pa -
tients were young females, consistent with previous
reports. Patients were usually admitted to the acute
wards and were cared for by internal physicians, indi-
cating that complications of lupus disease often
develop acutely and are unlikely to require surgical
intervention. However, it should be noted that
rheumatologists only covered around one third of
dead SLE patients for their end-of-life hospitalizations
in Taiwan. This phenomenon indicated that SLE itself
is manifested with multi-organ involvement and dam-
age. Thus, patients with SLE were admitted with lethal
complications from different involved organs/systems,
for which the specialists were assigned to care. Our
results suggest that internal physicians should have
relevant knowledge and capacity to care for patients
with SLE, and rheumatologists should take more
responsibility to consult or combine care for compli-
cated SLE patients in Taiwan.
For the costs and pathway of care  
in end-of-life SLE
Regarding the medical costs for SLE, Pelletier 
et al. reported an impact of co-existing nephropa-
thy on higher inpatient and outpatient expenses
[14]. In the USA, the inpatient costs for SLE have
increased to a mean of 10,000 USD for each admis-
sion [6]. In Taiwan, the mean inpatient cost for SLE
was lower than those in the USA, totaling 1,923
USD for each admission [10]. In this study, the mean
cost for each end-of-life hospitalization was more
expensive (9,530 ±10,354 USD) than those report-
Table IV. Major comorbidities in the end-of-life hos-
pitalization of patients with SLE during 2005-2007
(N = 302)
Comorbidities No. (%)
Sepsis or bacteremia 127 (42.1)
Acute respiratory failure 117 (38.7)
Shock, non-traumatic 63 (20.9)
Acute myocardial infarction 8 (2.6)
Acute cerebrovascular accident 31 (10.3)
Acute lower respiratory conditions 81 (26.8)
Urological infections 23 (7.6)
Peptic ulcer or esophagitis 12 (4.0)
Hypertensive diseases 32 (10.6)
Heart failure 23 (7.6)
Diabetes mellitus 15 (5.0)
Cancers 27 (8.9)
Nephropathy/nephritis 106 (35.1)
Table V. Correlation of individual factors with each other in SLE patients approaching death, calculated by multi-
variate logistic regression
Dependent variable Covariates B OR 95% CI Value of p
Age ≥ 65 years Nephropathy/nephritis –0.974 0.377 0.181-0.789 0.010
ALRC 0.880 2.411 1.282-4.535 0.006
Diabetes mellitus 1.935 6.926 2.264-21.187 0.001
Male gender 1.022 2.778 1.300-5.935 0.008
Nephropathy/nephritis Hospital stay > 14 days 0.566 1.761 1.080-2.871 0.023
Cancers –2.006 0.135 0.031-0.582 0.007
Acute respiratory failure ALRC 0.733 2.081 1.235-3.506 0.006
Cancers –1.092 0.336 0.122-0.921 0.034
Shock, non-traumatic Hospital stay ≤ 14 days 0.901 2.463 1.312-4.608 0.005
ALRC –0.855 0.425 0.194-0.933 0.033
Sepsis or bacteremia 1.852 6.369 3.304-12.277 < 0.001
Cancers –2.716 0.113 0.014-0.911 0.041
B – regression coefficient, OR – odds ratio, CI – confidence interval, ALRC – acute lower respiratory condition
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ed in the aforementioned epidemiological studies.
Regarding the details of cost, a large proportion was
allocated to drug prescriptions to maintain vital
organs as well as the laboratory tests accompany-
ing these tasks. It is conceivable that late compli-
cations of SLE are so extensive and catastrophic
that they would account for most of the life-long
treatment costs. Interestingly, subjects who re -
ceived hospice care had significantly lower total
costs for end-of-life hospitalization than the oth-
ers (1,664 ±3,014 vs. 9,744 ±10,401 USD, p < 0.001
by two-sample t-test). The cost-saving benefits of
hospice care have been confirmed by previous stud-
ies and might be considered as an alternative way
to care for terminal SLE patients [15-17].
For acute/chronic comorbidities in end-of-life
SLE
The acute comorbidities in end-of-life SLE
patients provided clues to the mortality issues. In
other countries or areas, previous epidemiological
and hospital-based studies have identified infec-
tions as the leading cause of death in SLE patients
[18-20]. In Taiwan, Feng et al. reported that inade-
quate use of antibiotics and prolonged hospital
stays increased the mortality of SLE patients in
intensive care units [21]. Similarly, our results
demonstrated that sepsis/bacteremia, acute respi-
ratory failure and ALRC were the three most com-
mon acute comorbidities in dying SLE patients.
These conditions are likely to have a major impact
on SLE patients during their end of life. We sup-
posed that hematogenous infections were the most
difficult factor to deal with in terms of treating
patients with life-threatening SLE.
Among the chronic comorbidities, nephropa-
thy/nephritis prevailed in dying SLE patients. This
was consistent with reports showing a high preva-
lence of lupus renal diseases in Orientals [22]. Anoth-
er study has also reported an increasing trend of
Medicare expense in parallel to the increasing inci-
dence of renal damage in SLE patients [23]. In this
study, we can see that nephropathy/nephritis in SLE
patients claimed significantly higher total expens-
es for hospitalization, particularly during the end of
life (11,710 ±10,885 vs. 8,351 ±9,885, p = 0.007 by
two-sample t-test), although relatively longer hos-
pital stay might be a confounding factor. This sug-
gests that early prevention or treatment of
nephropathy/nephritis is an essential requirement
to save costs that may be ultimately incurred by pro-
longed and expensive treatment for catastrophic
complications of SLE.
Our results have demonstrated that 5% of dying
SLE patients had concurrent DM, a figure similar to
those reported elsewhere. It has been widely
accepted that patients with SLE have a higher risk
for metabolic syndrome, coronary artery disease
and/or stroke [24, 25]. Our results showed a high-
er prevalence of DM in male SLE patients approach-
ing death (7.3% vs. 4.7-6.5% in general male po -
pulation; 4.6% vs. 5.3-6.6% in general female
po pulation) in Taiwan [26]. Also, the prevalence of
acute cerebrovascular accidents in our patients was
higher than those reported previously [27, 28]. On
the other hand, occurrence of acute myocardial
infarction was similar to those reported endemi-
cally [29]. These have suggested that prolonged
inflammation or autoimmune processes can lead
to the development of vascular damage that sub-
sequently results in fatal cerebrovascular or car-
diovascular episodes.
For relationships of logistic regressions
Significant associations or correlations have been
observed in this study. For example, older patients
tended to have more chance of getting diabetes,
patients with ALRC were more prone to acute res-
piratory failure, and patients with non-traumatic
shock tended to have sepsis/bacteremia as their
cause. We supposed that these conditions could be
induced by glucose intolerance and immunosup-
pressive status after long-term use of corticos-
teroids. In addition, it is interesting that nephropa-
thy was more frequently identified in younger
patients and associated with a prolonged hospital
stay. Regarding the latter, no compelling data could
support this finding up to now. It needs further clar-
ification. Regarding the former, Pelletier et al.
demonstrated a similar risk in American SLE popu-
lations [14]. Another Canadian study also reported
a higher incidence of nephropathy in younger
patients with early onset of illness in non-Caucasian
pediatric SLE patients [30]. Furthermore, more rap-
id progression of nephropathy and lower survival
rates were reported in non-Caucasian SLE patients
[31]. Our results demonstrated a similar character-
istic of nephropathy/nephritis, including LN. This
suggests that earlier diagnosis and control of
nephropathy are essential for reducing mortality
rates and medical costs in SLE patients.
Non-traumatic shock was associated with short-
er hospital stays and fewer ALRC. The most likely
cause of shorter hospitalization time was rapid
deterioration course resulting in death in these
immunosuppressive patients. This reflected the
impact of shock on the progression of the illness.
The association between fewer ALRC and more non-
traumatic shock implied that the major pattern of
infections might be sepsis/bacteremia without spe-
cific origins in critical SLE patients due to their poor-
er immunosuppressive status. Actually, in many
patients dying of septic shock the original source
of infection could not be definitely identified. So,
occult infections should be looked for and careful-
ly evaluated for every critical SLE patient [32].
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Another interesting issue was that elderly
patients (age ≥ 65 years) tended to be male and to
have ALRC. A previous local epidemiological study
reported a definitely better prognosis in young-mid-
dle aged female SLE patients and a lower survival
rate of male SLE patients in Taiwan [10]. The rea-
sons for the discrepancy with previous reports are
unknown. It is possible that male patients with SLE
have been overlooked and underestimated in Tai-
wan owing to a low index of suspicion by clinical
practitioners other than rheumatologists because
of overwhelming comorbidities, and by patients
and their families. The higher ratio of ALRC implied
that respiratory tract infections constitute a major
problem in elderly SLE patients. Relevant studies
were rare in aged SLE patients because their counts
were limited. Further extensive cohort investiga-
tions may be necessary to clarify this point.
The understanding of the implications and path-
ogenic relevance of comorbid cancers in SLE has
changed in the past decade. Recent studies have
demonstrated an increased incidence of cervical,
bladder, lung and hematological cancers in SLE
patients [33, 34]. Chen et al. have reported an over-
all increased risk of cancers in Taiwanese SLE
patients [35]. Our results demonstrated similar fea-
tures in critical SLE patients, although the number
of patients enrolled was much lower than in other
investigations. The reason why these comorbid can-
cers involve the hematological, respiratory and gen-
itourinary systems is unknown. Further in-depth
investigation is mandatory to determine whether
long-term immunosuppressive medications or sim-
ilar immunopathogenetic mechanisms with SLE
caused comorbid cancers. On the other hand, the
absence of a correlation between cancer incidence
and some acute illnesses in dying SLE patients sug-
gests that lethal infections may be more important
factors in causing death than associated cancers.
Similarly, the lack of association between cancers
and chronic illness such as nephropathy/nephritis
has indicated that renal inflammation may not be
an essential factor for the development of malig-
nancies in aged SLE patients. Further investigations
may be necessary to clarify the issue.
There were a few limitations in this study. Pos-
sible errors in registration of the patients are
unavoidable in a large population of patients like
this. Absence of detailed relevant laboratory data,
specific serum markers and records of immuno-
suppressive prescriptions in claim data restricted
the power of the study to evaluate the activity or
severity of SLE itself. Absence of linkage with a mor-
tality dataset also limited the in-depth approach to
cause of death due to official and legal limitations.
LN could not be discussed separately from
nephropathy/nephritis owing to limitations of pres-
ent ICD-9-CM coding. Nevertheless, the present
investigation constitutes a novel approach to study
the SLE patients on the verge of death on a nation-
wide scale. Further case-controlled or cohort stud-
ies are necessary for a more in-depth understand-
ing of the natural course of SLE.
In conclusion, a survey of the end-of-life hospi-
talization of patients with SLE has identified the
various characteristics of these patients during the
end stage of the disease. Sepsis/bacteremia, acute
respiratory failure, and ALRC were common acute
co-morbidities in dying SLE patients. Nephropa-
thy/nephritis mainly manifested in younger sub-
ject. Elderly SLE patients presented with unique
characteristics during the last period of survival,
which require further assessment. The difficulties
in the care of SLE inpatients challenge healthcare
providers, who require more awareness to reduce
disease per se or complications in dying SLE
patients.
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